2023 SGBCC Expert Voting: Radiotherapy

2023 SGBCC Expert Voting: Radiotherapy

2023.10.24
The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, known as the "City of Music", from March 15th to 18th, 2023, local time. SGBCC brought together breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics regarding early-stage breast cancer treatment. This culminates in the St.Gallen early-stage breast cancer international expert consensus, which is updated every two years. On the last day of the conference, the expert voting was the highlight. 
2023 SGBCC Expert Voting: Endocrine Therapy and Chemotherapy Decision for ER-Positive Breast Cancer

2023 SGBCC Expert Voting: Endocrine Therapy and Chemotherapy Decision for ER-Positive Breast Cancer

2023.10.24
The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "World Music Capital," from March 15 to 18, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in early breast cancer diagnosis and treatment, forming an updated St.Gallen International Expert Consensus on Early Breast Cancer every two years. On the final day of the conference, expert voting took center stage. Oncology Frontier  has compiled expert votes on two topics: adjuvant endocrine therapy and chemotherapy decisions for ER-positive breast cancer.
2023 SGBCC Expert Voting: Pathology, Genes, DCIS, Male Breast Cancer

2023 SGBCC Expert Voting: Pathology, Genes, DCIS, Male Breast Cancer

2023.10.24
The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music", from March 15 to 18, 2023 local time. SGBCC gathered breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics related to early-stage breast cancer treatment. This forms the St.Gallen Early Breast Cancer International Expert Consensus, which is updated every two years. "Oncology Frontier" has compiled expert votes on topics related to early breast cancer's pathology, genes, DCIS, and male-related issues. Let's experience the St.Gallen atmosphere of early breast cancer treatment decision-making.
2023 SGBCC Expert Voting: HER2 Positive, BRCA Associated,  Bone Modifying Therapy, Molecular Diagnosis

2023 SGBCC Expert Voting: HER2 Positive, BRCA Associated,  Bone Modifying Therapy, Molecular Diagnosis

2023.10.24
The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, known as the "Capital of World Music", from March 15th to 18th, 2023 local time. On the last day of the conference, the highlight was the expert voting session. Oncology Frontier  has  compiled expert voting on the treatment of HER2 positive breast cancer, BRCA Associated treatment,  Bone Modifying Therapy , oligo-metastatic disease, and molecular diagnosis topics. Additionally, a selection of these topics was presented for readers to vote on, allowing them to immerse themselves in the St.Gallen atmosphere of early breast cancer treatment decision-making.
IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030

IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030

2023.10.22
On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized the importance of science as the foundation of policy and practice, highlighting the close integration of science, policy, and activism to promote significant advancements in the HIV and AIDS sector. The theme of the conference is "End Inequalities. End AIDS. End Pandemics.", reflecting IAS's ultimate vision. The goal is to rally health experts globally towards the shared ambition of eradicating AIDS by 2030.
IAS 2023 | WHO Guidelines Update: The Risk of HIV Sexual Transmission with Low Viral Load is Nearly Zero

IAS 2023 | WHO Guidelines Update: The Risk of HIV Sexual Transmission with Low Viral Load is Nearly Zero

2023.10.22
The 12th International AIDS Society Conference on HIV Science (IAS 2023) began on July 23, 2023, in Brisbane, Australia. At the conference, experts from the World Health Organization (WHO) introduced important updates to the HIV guidelines, emphasizing the importance of "HIV viral suppression for improved individual health and reduced transmission." On the eve of the conference, The Lancet published a systematic review showing that the risk of HIV transmission with low-level viral load is almost zero.
IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

2023.10.22
Integrase strand transfer inhibitors (INSTIs) are associated with weight gain, but this weight gain doesn't harm survival or increase cardiovascular disease (CVD) risk. So, does the weight gain associated with INSTIs lead to a higher risk of diabetes? At the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), the renowned RESPOND cohort study from Europe and America indicated that INSTIs might increase the risk of diabetes onset. Even after adjustment, the onset risk remains statistically significant.
IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV

IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV

2023.10.22
People Living With HIV (PLWH) are at high risk of active tuberculosis (TB). Guidelines both domestically and internationally suggest that PLWH with positive latent tuberculosis infection (LTBI) screening and those with a history of close contact with active TB should receive TB preventive treatment. However, commonly used preventive treatment regimens such as rifampin and rifapentine have potential drug interactions with HIV antiretroviral therapy (ART). A multi-center retrospective study from Taiwan, China, presented at the 12th International AIDS Society HIV Science Conference (IAS 2023) showed that ART based on integrase inhibitors (INSTIs) combined with rifapentine-based short-course TB preventive treatment does not affect the patient's sustained HIV virologic suppression rate.
IAS 2023 | South African study indicates that HIV male patients have a greater likelihood of achieving virological remission than females.

IAS 2023 | South African study indicates that HIV male patients have a greater likelihood of achieving virological remission than females.

2023.10.22
 In the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), a research study from South Africa found that, despite seldom adhering to antiretroviral therapy (ART), 5 male children who were born with HIV still maintained undetectable viral loads. Researchers believe that due to innate immunological gender differences, boys might have a better chance of achieving sustained virological remission than girls.
IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

2023.10.22
The 12th International AIDS Association HIV Science Conference (IAS 2023) was held in Brisbane, Australia from July 23 to 26, 2023. In the oral reports of the conference, experts from the World Health Organization (WHO) reported that global monitoring data for MPOX in 2022 showed that half of the patients with MPOX were HIV carriers. However, HIV is not a risk factor for increased hospitalization due to MPOX. Another study based on interviews with MPOX patients in Australia indicated that most patients had negative experiences with the disease and sequelae related to MPOX.